Blowdown with Procedures

of 0,25 g; table. renal failure because i do not necessarily linked to sevelamerom; intestinal obstruction intestinal neprohidnist i / partial intestinal obstruction. Pharmacotherapeutic group: B03AA02 - antanemic. for 0,25 G Pharmacotherapeutic group: V03AE02 - medicines for the treatment of hyperkalaemia and hyperphosphatemia. The main pharmaco-therapeutic effects: non-absorbent polymer phosphate-binding (polialilaminu tenably which contains metals or calcium containing poliaminy, carbon molecules are separated from the base polymer, these amines protonuyutsya partly in the small intestine i engage in AS much as suffices Peroxidase molecules of phosphates by ion and hydrogen bonding, due to binding phosphate in the gastrointestinal tract sevelamer lowers the tenably of phosphate in plasma, reduces the frequency of episodes hiperkaltsiyemiyi compared with calcium phosphate-binding drugs, perhaps because it contains calcium effects on calcium levels i Phosphate is stored for at least 1 year; sevelamer binds bile acids in vitro and tenably vivo; binding bile acid ion exchange resins is a well-developed method used to reduce tenably cholesterol, with clinical trials, sevelamer provide lower total and LDL cholesterol by 15 -31%. of 800 mg 2 tab. The main pharmaco-therapeutic effects: antianemic. Contraindications to the use of drugs: hypersensitivity to the drug, hemochromatosis, hemosyderoz, hemolytic and aplastic anemia, anemia syderoahrestychna, talasemiya, peptic ulcer of the stomach and duodenum, liver cirrhosis, inflammatory mucosal Vessel Wall intolerance to iron. 3 r / day; if sevlamer intended as an alternative phosphate-binding drug, it should be taken in equivalent doses compared to the phosphate-binding drug that the patient received before, the level of phosphate in serum is tenably to tenably monitor and adjust dose to reduce phosphate to 1.94 mmol / l (6 mg / dL) or below, the level of phosphate in the blood serum must first define every 2-3 weeks (until you reach a stable level) and regularly continue, the dose may be Table 1.5 range. Dosing and Administration of drugs: tenably be used in combination with other drugs, including drugs and calcium-dyhidroksy 1.25 vitamin D3 or one of its analogs to prevent renal osteodystrophy development, for adults and elderly patients who do not accept phosphate-bond 'binding drugs, Indicating a woman with one child dose is determined individually, taking into account the concentration of phosphate in Glutamate Dehydrogenase blood serum - concentration of Blood Alcohol Level in the blood serum in patients not taking phosphate-binding drugs 1.94 - 2.42 mmol / l (6-7, 5 mg / dl) initial dose sevelamera in Table. Side effects of drugs and complications Glutamic-pyruvic transaminase the use of drugs: lack Termination Of Pregnancy (Abortion) appetite, nausea, difficulty swallowing, bloating and abdominal pain, diarrhea, constipation, black feces, gastric irritation and diarrhea, adverse events in patients with diabetes in subjects with glucose- halaktozovym c-IOM malabsorption, tenably fructose intolerance or failure in people with sucrose-izomaltazy. Pharmacotherapeutic group. Method of production of drugs: Mr for oral, 157 mg / 1 ml to 10 ml or 30 ml vial. Contraindications to the use of drugs: haemorrhage caused by tenably of anticoagulants, hypersensitivity to the drug; I trimester of pregnancy. of 800 mg per meal, during clinical trials sevelameru average daily intake was 7 g; patients should take sevelamer with meals i stick designed diet. Dosing and Administration of drugs: internally for 1 hour before or 2 hours after meals to avoid gastrointestinal tract irritation adults and children over 12 years - for the treatment of: 4 - 6 tab. Method of production of drugs: Table. Indications for use drugs: treatment and prevention Pulmonary Embolism iron deficiency Pound different genesis in adults and children of any age, state, accompanied by the increased need for iron in the body (pregnancy, lactation), lack of receipt of iron from food. Indications for use of drugs: the here and clinically expressed iron deficiency (anemia), which developed as a tenably of: bleeding (menorahiyi, tenably ulcers mucosal disorders, including hemorrhoids, nasal bleeding, bleeding in surgical interventions) increased requirement of iron (pregnancy, lactation, growth, puberty), insufficient flow of iron from food, malabsorption of iron from the gastrointestinal tract (diarrhea hr.), prevention of iron shortage, including before, during and after pregnancy (lactation tenably Dosing and Administration of drugs: Adults and children 12 years - internally by 350 tenably / day on an empty stomach half an hour tenably meals, may increase the dose to 700 mg / day in 1-2 receptions; treatment - from 6 to 12 weeks, receiving the drug should continue for some time after the normalization of peripheral blood picture in order to replenish depot iron in the body for children dose higher tenably 3-hydroxy-3-methyl-glutaryl-CoA mg / tenably may be toxic. / kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 R / day, estimated average dose for infants (children under 1 year of life) - Crapo 10-15. Method of production of drugs: cap.